

**From:** [Trials](#)  
**To:** [Deborah Sterling](#); [Trials](#)  
**Cc:** [Eric Stops](#); [Nick Cerrito](#); [John Galanek](#); [Frank Calvosa](#); [Daniel Wiesner](#); [Olga A. Partington](#)  
**Subject:** RE: PGR2019-00048 - request for conference call  
**Date:** Thursday, September 12, 2019 1:27:51 PM  
**Attachments:** [image001.png](#)  
[image002.png](#)

---

Counsel:

Petitioner is authorized to file to file a 3-page Reply to Corcept's Preliminary Patent Owner Response ("POPR") to address statements in Corcept's POPR regarding the schedule of the concurrent litigation involving the '214 patent. Petitioner's Reply shall be filed on or before September 23, 2019. Patent Owner is authorized to file a Sur-Reply to Petitioner's Reply. Patent Owner's Sur-Reply shall be filed on or before October 3, 2019. We will issue an order to this effect in due course.

Regards,

Andrew Kellogg,  
Supervisory Paralegal  
Patent Trial and Appeal Board  
USPTO  
[andrew.kellogg@uspto.gov](mailto:andrew.kellogg@uspto.gov)  
Direct: 571-272-5366

---

**From:** Deborah Sterling <DSTERLING@sternekessler.com>  
**Sent:** Wednesday, September 11, 2019 10:32 AM  
**To:** Trials <Trials@USPTO.GOV>  
**Cc:** Eric Stops <ericstops@quinnemanuel.com>; Nick Cerrito <nickcerrito@quinnemanuel.com>; John Galanek <johngalanek@quinnemanuel.com>; Frank Calvosa <frankcalvosa@quinnemanuel.com>; Daniel Wiesner <danielwiesner@quinnemanuel.com>; Olga A. Partington <OPARTINGTON@sternekessler.com>  
**Subject:** PGR2019-00048 - request for conference call

Dear Board,

I write on behalf of Petitioner Teva Pharmaceuticals USA, Inc. to respectfully request a conference call with the Board in PGR2019-00048. Teva wishes to request authorization to file a 3-page reply to Corcept's Preliminary Patent Owner Response to address certain statements in Corcept's POPR that mischaracterize the schedule of the concurrent litigation involving the '214 patent.

The parties have met and conferred and counsel for Corcept has advised that Corcept will not oppose Teva's request for a reply if Teva does not oppose a request from Corcept to file a 3-page sur-reply. Teva has agreed to not oppose a sur-reply if Teva is authorized to file a reply.

The parties are available for a call at the Board's convenience between 10 am – 5 pm Eastern time on September 12 or 13, to address why good cause exists.

Respectfully submitted,

Deborah Sterling (Counsel for Petitioner)



**Deborah Sterling, Ph.D.**

Director

**Sterne, Kessler, Goldstein & Fox P.L.L.C.**

1100 New York Avenue, NW, Washington, DC 20005

---

**Email:** [dsterling@sternekessler.com](mailto:dsterling@sternekessler.com)

**Direct:** 202.772.8501

**IP Assistant:** Katherine Valencia

**Direct:** 202.772.8937 **Main:** 202.371.2600

Notice: The information in this electronic transmission (including any attachments) may contain confidential or legally privileged information and is intended solely for the individual(s) or entity(ies) named above. If you are not an intended recipient or an authorized agent, you are hereby notified that reading, distributing, or otherwise disseminating or copying, or taking any action based on the contents of this transmission is strictly prohibited. Any unauthorized interception of this transmission is illegal under the law. If you have received this transmission in error, please immediately notify the sender by return email and then destroy all copies of the transmission.